A detailed history of Woodline Partners LP transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 842,892 shares of ELDN stock, worth $3.26 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
842,892
Previous 675,243 24.83%
Holding current value
$3.26 Million
Previous $1.78 Million 17.73%
% of portfolio
0.02%
Previous 0.02%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.41 - $3.19 $404,034 - $534,800
167,649 Added 24.83%
842,892 $2.1 Million
Q2 2024

Aug 14, 2024

BUY
$1.57 - $3.12 $36,587 - $72,708
23,304 Added 3.57%
675,243 $1.78 Million
Q1 2024

May 15, 2024

SELL
$1.54 - $2.13 $57,597 - $79,664
-37,401 Reduced 5.43%
651,939 $1.34 Million
Q4 2023

Feb 14, 2024

BUY
$1.12 - $1.86 $95,588 - $158,745
85,347 Added 14.13%
689,340 $1.24 Million
Q3 2023

Nov 14, 2023

BUY
$1.14 - $1.66 $99,542 - $144,947
87,318 Added 16.9%
603,993 $827,000
Q2 2022

Aug 15, 2022

SELL
$2.34 - $3.96 $366,123 - $619,593
-156,463 Reduced 23.24%
516,675 $1.26 Million
Q1 2022

May 16, 2022

SELL
$3.06 - $4.89 $331,208 - $529,283
-108,238 Reduced 13.85%
673,138 $2.65 Million
Q3 2021

Nov 15, 2021

SELL
$5.94 - $8.46 $451,849 - $643,543
-76,069 Reduced 8.87%
781,376 $4.83 Million
Q2 2021

Aug 16, 2021

SELL
$7.62 - $11.75 $256,108 - $394,917
-33,610 Reduced 3.77%
857,445 $6.78 Million
Q1 2021

May 17, 2021

BUY
$9.85 - $19.22 $8.78 Million - $17.1 Million
891,055 New
891,055 $9.53 Million

Others Institutions Holding ELDN

About Eledon Pharmaceuticals, Inc.


  • Ticker ELDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,756,800
  • Market Cap $53.2M
  • Description
  • Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...
More about ELDN
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.